$PTN H.C. Wainwright analyst Joseph Pantginis is behind today’s news as he reiterated the firm’s buy rating for PTN stock. To go along with that, Pantginis also increased the price target for PTN stock from $2 per share to $5 per share, 1,371% upside Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the...
Company Profile Sector: Health Care Industry: Biotechnology Company Location: Cranbury, NJ Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of...
I really don't see it going below the green line. Good time to load up imo.
These thoughts are my own ideas based off my own analysis. Please do your own research before putting your own money into the markets.
I just created this chart to better understand how PTN moved on the big spike recently. Seems like it didn't take much, just a Yahoo article after the positive dry eye news and then a few YouTube videos. Here are the links to the article and videos: 12/22/2020 Michael Marcus -...
Short Term - Break .61-.62 for .75 target. Long Term - Expect NA and ROW licensing deals to push above $2 before the end of 2021.
PTN gave a nice buy signal. I personally took a position here. There is a chance it could test 0.40 cent area. Stoploss below white line, take profits at colored lines above green. THIS IS NOT FINANCIAL ADVICE. DO NOT BLINDLY FOLLOW THIS TRADE.
Let's see if volume confirms this breakout. A lot going on with this company right now. I believe with the Key Opinion Leader webinar tomorrow they are trying to increase institutional buying and possibly analyst coverage. Volatility with the stock over the past 5 years has allowed quite a bit of opportunity to repeatedly buy below .60 and sell above 1.20.
Chart gives ~.72 target. Also breaking above 200MA
This is about 40% return if it hits this upper target.
Although my target based on fundamentals is much higher for PTN. This harmonic pattern gives a .72 target. Link below to my other PTN idea with fundamental outlooks on how we look moving forward.
Looking at the pattern between the buy and sell periods, it looks like maybe one more step sown or continued accumulation before the buy set up is initiated. Looking at an end of april to a begining of june bull run for ptn and with the upcoming catalysts, shoud see a price increase from 1.50-2.75
Palatin Technologies is a little known pharmaceutical company that specializes in the development of peptide drugs. Palatin Technologies (PTN) is severely undervalued with a Market Cap of about $180 Million as of 3/17/21. Palatin has $72.2 Million in cash on hand as of 12/31/2020, and no debt.* Palatin owns and recently began marketing FDA Approved Vyleesi, a drug...
Analysts have a price target between $2 and $3. Earnings report on 17 Feb 2021. They launch their first FDA-approved product Vyleesi to market in Q3 of 2020 which could potentially help 6 million women suffering from HSDD in the USA alone. This product generated $800 million in sales in Q3 and will grow over time as Palatin is currently the only company offering...
Canaccord Genuity analyst John Newman maintained a Buy rating on Palatin Technologies yesterday and set a price target of $3.00. According to TipRanks.com, Newman is a 5-star analyst with an average return of 24.5% and a 44.8% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and...
Very Strong Fundamentals..........AND ..........double CUP ...........UP.....UP....UP!!!!
Broke the sideway trend final elliot wave completion to be predicted this coming week